BiotechTube
Curadel Pharma

Curadel Pharma

San Diego, United States· Est.
curadelpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Curadel Pharma is an innovator in radiopharmaceuticals, pioneering a novel 'Audacious Alpha' platform based on zwitterionic chemistry to create targeted alpha therapies with an improved therapeutic window. Its technology is designed to minimize off-target toxicity and prevent tumor resistance, addressing key limitations of current radiotherapies. The company has a Phase 3 program for an optical imaging agent (ZW800-1) and is advancing its early-stage oncology pipeline with $10.5M in Series A2 funding. Led by a team with deep expertise in zwitterionicity and drug development, Curadel aims to redefine outcomes in challenging metastatic cancers.

OncologySurgical Imaging

Technology Platform

Proprietary zwitterionic technology platform (Audacious Alpha™) for designing drugs that minimize off-target binding and enable rapid renal clearance, aimed at improving the therapeutic window of targeted alpha therapies and imaging agents.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The rapidly expanding radiopharmaceutical market, particularly for targeted alpha therapies, presents a multi-billion dollar opportunity.
Curadel's platform, if successful, could capture significant value by addressing the key limitations of toxicity and resistance that hinder current therapies.
Additionally, the near-term potential approval and commercialization of ZW800-1 provides a non-dilutive funding source and validates the platform's applicability.

Risk Factors

The company faces high clinical risk as its core oncology platform is unproven in humans, and it operates in the capital-intensive biotech sector with substantial future funding needs.
It also competes in a crowded and fast-moving radiopharma landscape against large, well-resourced companies.

Competitive Landscape

Curadel competes in the targeted alpha therapy space against companies like Bayer (Xofigo), Actinium Pharmaceuticals, and AAA/Novartis (invested in alpha therapies), and in the surgical imaging space against existing dyes and agents. Its differentiation hinges on the unique safety and efficacy profile promised by its zwitterionic chemistry, which aims to be best-in-class.

More companies in Radiopharmaceuticals →More companies in United States →